[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Takamiya et al., 2002 - Google Patents

Human factor VII deficiency caused by S339C mutation located adjacent to the specificity pocket of the catalytic domain

Takamiya et al., 2002

Document ID
15319946554406991586
Author
Takamiya O
Seta M
Tanaka K
Ishida F
Publication year
Publication venue
Clinical & Laboratory Haematology

External Links

Snippet

This report documents our identification of a novel factor VII (FVII) gene mutation in a Japanese boy with FVII deficiency. The proband's FVII activity was 34% and his FVII antigen level was 40% of normal controls. DNA sequence analysis of the proband's FVII gene …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Similar Documents

Publication Publication Date Title
Green et al. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals.
Ljung et al. Haemophilia B mutations in Sweden: a population‐based study of mutational heterogeneity
Matsumoto et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome
Roemisch et al. The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP)
Bernardi et al. Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis
Medina et al. Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk
Millar et al. Molecular analysis of the genotype-phenotype relationship in factor VII deficiency
Montagnana et al. An overview of thrombophilia and associated laboratory testing
Peyvandi et al. Gene mutations and three‐dimensional structural analysis in 13 families with severe factor X deficiency
Bereczky et al. Protein C and protein S deficiencies: similarities and differences between two brothers playing in the same game
Henriksen et al. Prothrombin Greenville, Arg517→ Gln, identified in an individual heterozygous for dysprothrombinemia
Martincic et al. Identification of mutations and polymorphisms in the factor XI genes of an African American family by dideoxyfingerprinting
Takamiya et al. Human factor VII deficiency caused by S339C mutation located adjacent to the specificity pocket of the catalytic domain
Christiansen et al. The effect of a single nucleotide polymorphism on human α2-antiplasmin activity
Zhang et al. Endogenous plasmin converts Glu-plasminogen to Lys-plasminogen on the monocytoid cell surface
Awidi et al. Study of mutations in Jordanian patients with haemophilia A: identification of five novel mutations
Kemkes‐Matthes et al. R255h amino acid substitution of protein Z identified in patients with factor V Leiden mutation
Corral et al. Factor XIII Val 34 Leu polymorphism in primary intracerebral haemorrhage
EP0846185B1 (en) T-pa polymorphism and use thereof in diagnosis of risk of thrombus associated disease
Shen et al. Novel mutations in the Factor VII gene of Taiwanese Factor VII‐deficient patients
Hewitt et al. Severe FVII deficiency caused by a new point mutation combined with a previously undetected gene deletion
Tamura et al. In vitro exploration of latent prothrombin mutants conveying antithrombin resistance
Goel et al. ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension
Nagaizumi et al. Two double heterozygous mutations in the F7 gene show different manifestations
Lippi et al. Genomics and proteomics in venous thromboembolism: building a bridge toward a rational personalized medicine framework